124 related articles for article (PubMed ID: 38621603)
1. The impact of phospholipids with high transition temperature to enhance redox-sensitive liposomal doxorubicin efficacy in colon carcinoma model.
Mirhadi E; Askarizadeh A; Farhoudi L; Mashreghi M; Behboodifar S; Alavizadeh SH; Arabi L; Jaafari MR
Chem Phys Lipids; 2024 Jul; 261():105396. PubMed ID: 38621603
[TBL] [Abstract][Full Text] [Related]
2. Redox-sensitive doxorubicin liposome: a formulation approach for targeted tumor therapy.
Mirhadi E; Mashreghi M; Askarizadeh A; Mehrabian A; Alavizadeh SH; Arabi L; Badiee A; Jaafari MR
Sci Rep; 2022 Jul; 12(1):11310. PubMed ID: 35788647
[TBL] [Abstract][Full Text] [Related]
3. The Effect of Phase Transition Temperature on Therapeutic Efficacy of Liposomal Bortezomib.
Korani M; Nikoofal-Sahlabadi S; Nikpoor AR; Ghaffari S; Attar H; Mashreghi M; Jaafari MR
Anticancer Agents Med Chem; 2020; 20(6):700-708. PubMed ID: 31893998
[TBL] [Abstract][Full Text] [Related]
4. Liposomal formulation of Galbanic acid improved therapeutic efficacy of pegylated liposomal Doxorubicin in mouse colon carcinoma.
Nik ME; Malaekeh-Nikouei B; Amin M; Hatamipour M; Teymouri M; Sadeghnia HR; Iranshahi M; Jaafari MR
Sci Rep; 2019 Jul; 9(1):9527. PubMed ID: 31267009
[TBL] [Abstract][Full Text] [Related]
5. Surface-modified cationic liposomes with a matrix metalloproteinase-degradable polyethylene glycol derivative improved doxorubicin delivery in murine colon cancer.
Askarizadeh A; Mashreghi M; Mirhadi E; Mehrabian A; Heravi Shargh V; Badiee A; Alavizadeh SH; Arabi L; Kamali H; Jaafari MR
J Liposome Res; 2024 Jun; 34(2):221-238. PubMed ID: 37647288
[TBL] [Abstract][Full Text] [Related]
6. The influence of phospholipid on the physicochemical properties and anti-tumor efficacy of liposomes encapsulating cisplatin in mice bearing C26 colon carcinoma.
Alavizadeh SH; Badiee A; Golmohammadzadeh S; Jaafari MR
Int J Pharm; 2014 Oct; 473(1-2):326-33. PubMed ID: 25051111
[TBL] [Abstract][Full Text] [Related]
7. A study on the role of cholesterol and phosphatidylcholine in various features of liposomal doxorubicin: From liposomal preparation to therapy.
Farzaneh H; Ebrahimi Nik M; Mashreghi M; Saberi Z; Jaafari MR; Teymouri M
Int J Pharm; 2018 Nov; 551(1-2):300-308. PubMed ID: 30243944
[TBL] [Abstract][Full Text] [Related]
8. Drug release rate influences the pharmacokinetics, biodistribution, therapeutic activity, and toxicity of pegylated liposomal doxorubicin formulations in murine breast cancer.
Charrois GJ; Allen TM
Biochim Biophys Acta; 2004 May; 1663(1-2):167-77. PubMed ID: 15157619
[TBL] [Abstract][Full Text] [Related]
9. Study of FA12 peptide-modified PEGylated liposomal doxorubicin (PLD) as an effective ligand to target Muc1 in mice bearing C26 colon carcinoma: in silico, in vitro, and in vivo study.
Biabangard A; Asoodeh A; Jaafari MR; Mashreghi M
Expert Opin Drug Deliv; 2022 Dec; 19(12):1710-1724. PubMed ID: 36373415
[TBL] [Abstract][Full Text] [Related]
10. Improvement in the drug delivery and anti-tumor efficacy of PEGylated liposomal doxorubicin by targeting RNA aptamers in mice bearing breast tumor model.
Moosavian SA; Abnous K; Badiee A; Jaafari MR
Colloids Surf B Biointerfaces; 2016 Mar; 139():228-36. PubMed ID: 26722819
[TBL] [Abstract][Full Text] [Related]
11. Improving anti-tumour efficacy of PEGylated liposomal doxorubicin by dual targeting of tumour cells and tumour endothelial cells using anti-p32 CGKRK peptide.
Mashreghi M; Faal Maleki M; Karimi M; Kalalinia F; Badiee A; Jaafari MR
J Drug Target; 2021 Jul; 29(6):617-630. PubMed ID: 33393376
[TBL] [Abstract][Full Text] [Related]
12. Preparation and characterization of PEGylated liposomal Doxorubicin targeted with leptin-derived peptide and evaluation of their anti-tumor effects, in vitro and in vivo in mice bearing C26 colon carcinoma.
Shahraki N; Mehrabian A; Amiri-Darban S; Moosavian SA; Jaafari MR
Colloids Surf B Biointerfaces; 2021 Apr; 200():111589. PubMed ID: 33545570
[TBL] [Abstract][Full Text] [Related]
13. Development of a bone-targeted pH-sensitive liposomal formulation containing doxorubicin: physicochemical characterization, cytotoxicity, and biodistribution evaluation in a mouse model of bone metastasis.
Ferreira Ddos S; Faria SD; Lopes SC; Teixeira CS; Malachias A; Magalhães-Paniago R; de Souza Filho JD; Oliveira BL; Guimarães AR; Caravan P; Ferreira LA; Alves RJ; Oliveira MC
Int J Nanomedicine; 2016; 11():3737-51. PubMed ID: 27563241
[TBL] [Abstract][Full Text] [Related]
14. Tat peptide and hexadecylphosphocholine introduction into pegylated liposomal doxorubicin: An in vitro and in vivo study on drug cellular delivery, release, biodistribution and antitumor activity.
Teymouri M; Badiee A; Golmohammadzadeh S; Sadri K; Akhtari J; Mellat M; Nikpoor AR; Jaafari MR
Int J Pharm; 2016 Sep; 511(1):236-244. PubMed ID: 27363937
[TBL] [Abstract][Full Text] [Related]
15. Vascular targeting of doxorubicin using cationic liposomes.
Wu J; Lee A; Lu Y; Lee RJ
Int J Pharm; 2007 Jun; 337(1-2):329-35. PubMed ID: 17275230
[TBL] [Abstract][Full Text] [Related]
16. A Novel Long-circulating DOX Liposome: Formulation and Pharmacokinetics Studies.
Xiao P; Zhao J; Huang Y; Jin R; Tang Z; Wang P; Song X; Zhu H; Yang Z; Yu N
Pharm Nanotechnol; 2020; 8(5):391-398. PubMed ID: 32787769
[TBL] [Abstract][Full Text] [Related]
17. In vivo anti-tumor effect of PEG liposomal doxorubicin (DOX) in DOX-resistant tumor-bearing mice: Involvement of cytotoxic effect on vascular endothelial cells.
Ogawara K; Un K; Tanaka K; Higaki K; Kimura T
J Control Release; 2009 Jan; 133(1):4-10. PubMed ID: 18840484
[TBL] [Abstract][Full Text] [Related]
18. Targeting CD44 expressing cancer cells with anti-CD44 monoclonal antibody improves cellular uptake and antitumor efficacy of liposomal doxorubicin.
Arabi L; Badiee A; Mosaffa F; Jaafari MR
J Control Release; 2015 Dec; 220(Pt A):275-286. PubMed ID: 26518722
[TBL] [Abstract][Full Text] [Related]
19. The role of size in PEGylated liposomal doxorubicin biodistribution and anti-tumour activity.
Dadpour S; Mehrabian A; Arabsalmani M; Mirhadi E; Askarizadeh A; Mashreghi M; Jaafari MR
IET Nanobiotechnol; 2022 Sep; 16(7-8):259-272. PubMed ID: 35983586
[TBL] [Abstract][Full Text] [Related]
20. Development and characterization of liposomal doxorubicin hydrochloride with palm oil.
Sabeti B; Noordin MI; Mohd S; Hashim R; Dahlan A; Javar HA
Biomed Res Int; 2014; 2014():765426. PubMed ID: 24795894
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
